董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Matthew Mackowski | 男 | Independent Director | 71 | 未披露 | 82.08 | 2026-06-01 |
| Brett Robertson | 女 | Director | 66 | 18.50万美元 | 7.24 | 2026-06-01 |
| Paul Grossman | 男 | Chairman of the Board | 65 | 未披露 | 0.92 | 2026-06-01 |
| Alexander Herzick | 男 | Director | 45 | 未披露 | 未持股 | 2026-06-01 |
| Alexander Vos | 男 | Independent Director | 63 | 18.00万美元 | 7.24 | 2026-06-01 |
| Stephen Gunstream | 男 | President and Chief Executive Officer, Director | 47 | 235.79万美元 | 160.86 | 2026-06-01 |
| Martha J. Demski | 女 | Independent Director | 73 | 18.75万美元 | 3.31 | 2026-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Gunstream | 男 | President and Chief Executive Officer, Director | 47 | 235.79万美元 | 160.86 | 2026-06-01 |
| Matthew Lowell | 男 | Chief Financial Officer | 55 | 121.20万美元 | 42.20 | 2026-06-01 |
| Damon Terrill | 男 | General Counsel and Chief Compliance Officer | 56 | 107.61万美元 | 30.15 | 2026-06-01 |
董事简历
中英对照 | 中文 | 英文- J. Matthew Mackowski
-
J. Matthew Mackowski，自2008年1月本公司成立之时起，担任本公司董事；2013年5月起，担任本公司的联席董事长。2006年起，他担任生物技术公司Althea Technologies, Inc的董事，直到2013年3月它被Ajinomoto 收购。他目前是Telegraph Hill Partners的董事长、董事总经理，这是一个专注于开发型生命科学、医疗技术公司的合伙投资企业；他于2001年加入该公司。他在Duke University获得学士学位，在The Wharton School获得工商管理硕士学位。
J. Matthew Mackowski,has served as a director since January 2019. Mr. Mackowski has been a healthcare-focused venture capital investor since 1980 and is Chairman and Managing Director of Telegraph Hill Partners, which he co-founded in 2001. Telegraph Hill Partners is a venture capital firm that takes an active role in developing technology-based growth companies in the life sciences, medical device, and healthcare industries, and has invested in 51 companies across five institutionally-funded limited partnerships. Mr. Mackowski formed Mackowski & Shepler, the predecessor to Telegraph Hill Partners, in 1992, and over nine years took an active or founding role with eight companies, primarily in medical and life science technologies. Mr. Mackowski currently represents Telegraph Hill Partners as a director of the following private portfolio companies: Kytopen Corp., Magstim, Inc., TrakCel Holding, Inc., and Emerging Therapy Solutions, Inc. Mr. Mackowski received a bachelor's degree from Duke University and an MBA from The Wharton School. - J. Matthew Mackowski，自2008年1月本公司成立之时起，担任本公司董事；2013年5月起，担任本公司的联席董事长。2006年起，他担任生物技术公司Althea Technologies, Inc的董事，直到2013年3月它被Ajinomoto 收购。他目前是Telegraph Hill Partners的董事长、董事总经理，这是一个专注于开发型生命科学、医疗技术公司的合伙投资企业；他于2001年加入该公司。他在Duke University获得学士学位，在The Wharton School获得工商管理硕士学位。
- J. Matthew Mackowski,has served as a director since January 2019. Mr. Mackowski has been a healthcare-focused venture capital investor since 1980 and is Chairman and Managing Director of Telegraph Hill Partners, which he co-founded in 2001. Telegraph Hill Partners is a venture capital firm that takes an active role in developing technology-based growth companies in the life sciences, medical device, and healthcare industries, and has invested in 51 companies across five institutionally-funded limited partnerships. Mr. Mackowski formed Mackowski & Shepler, the predecessor to Telegraph Hill Partners, in 1992, and over nine years took an active or founding role with eight companies, primarily in medical and life science technologies. Mr. Mackowski currently represents Telegraph Hill Partners as a director of the following private portfolio companies: Kytopen Corp., Magstim, Inc., TrakCel Holding, Inc., and Emerging Therapy Solutions, Inc. Mr. Mackowski received a bachelor's degree from Duke University and an MBA from The Wharton School.
- Brett Robertson
-
Brett Robertson自2010年9月起担任企业开发副总裁、总法律顾问和秘书。Robertson从2008年到2010年9月担任私人公司投资组合资本市场和增长战略执行官和董事顾问。Robertson从2006年到2007年担任StubHub（一家在线门票销售市场）高级副总裁和总法律顾问。Robertson从2003年到2006年担任Ask Jeeves（一家搜索引擎公司）执行副总裁和总法律顾问。Robertson持有伯克利the University of California文学学士学位以及the University of Virginia法律博士学位。
Brett Robertson,has served as a director since June 2021. Ms. Robertson served as the Chief Financial Officer of Vineti, Inc., a software-as-a-service platform for personalized therapies, from 2020 to 2022. Since 2016, she has been a member of the advisory board of AtlasMedx, Inc., a clinical stage biopharmaceutical company advancing targeted therapeutics that modulate antitumor pathways. From August 2016 to January 2019, Ms. Robertson served as the Chief Executive Officer of CureSeq, Inc., a company that develops and markets molecular diagnostics tests. From 2010 to 2016, Ms. Robertson served as the Chief Business Officer and General Counsel of Invuity, Inc., which was then acquired by Stryker Corporation (NYSE: SYK), a leading medical device technology company. From 2008 to 2010, Ms. Robertson was a venture partner at Leavitt Covington Ventures, LLC, a venture capital firm investing in software and technology, where she represented investors on multiple boards of directors to strategize and implement growth initiatives. Ms. Robertson served as Senior Vice President and General Counsel of StubHub, Inc. from 2006 to 2007, Executive Vice President and General Counsel of Ask Jeeves, Inc. from 2002 to 2005, Vice President of Strategic Development and General Counsel of Critical Path from 1999 to 2001, and General Counsel of Broderbund Software from 1993 to 1998. Ms. Robertson holds a bachelor's degree in anthropology from the University of California at Berkeley and a J.D. from the University of Virginia Law School. - Brett Robertson自2010年9月起担任企业开发副总裁、总法律顾问和秘书。Robertson从2008年到2010年9月担任私人公司投资组合资本市场和增长战略执行官和董事顾问。Robertson从2006年到2007年担任StubHub（一家在线门票销售市场）高级副总裁和总法律顾问。Robertson从2003年到2006年担任Ask Jeeves（一家搜索引擎公司）执行副总裁和总法律顾问。Robertson持有伯克利the University of California文学学士学位以及the University of Virginia法律博士学位。
- Brett Robertson,has served as a director since June 2021. Ms. Robertson served as the Chief Financial Officer of Vineti, Inc., a software-as-a-service platform for personalized therapies, from 2020 to 2022. Since 2016, she has been a member of the advisory board of AtlasMedx, Inc., a clinical stage biopharmaceutical company advancing targeted therapeutics that modulate antitumor pathways. From August 2016 to January 2019, Ms. Robertson served as the Chief Executive Officer of CureSeq, Inc., a company that develops and markets molecular diagnostics tests. From 2010 to 2016, Ms. Robertson served as the Chief Business Officer and General Counsel of Invuity, Inc., which was then acquired by Stryker Corporation (NYSE: SYK), a leading medical device technology company. From 2008 to 2010, Ms. Robertson was a venture partner at Leavitt Covington Ventures, LLC, a venture capital firm investing in software and technology, where she represented investors on multiple boards of directors to strategize and implement growth initiatives. Ms. Robertson served as Senior Vice President and General Counsel of StubHub, Inc. from 2006 to 2007, Executive Vice President and General Counsel of Ask Jeeves, Inc. from 2002 to 2005, Vice President of Strategic Development and General Counsel of Critical Path from 1999 to 2001, and General Counsel of Broderbund Software from 1993 to 1998. Ms. Robertson holds a bachelor's degree in anthropology from the University of California at Berkeley and a J.D. from the University of Virginia Law School.
- Paul Grossman
-
Paul Grossman自2019年1月起担任董事，并自2014年2月起担任风险投资公司Telegraph Hill Partners的合伙人，该公司积极参与生命科学，医疗器械和医疗保健行业中基于技术的成长型公司的发展。Grossman博士曾于2008年11月至2014年2月担任Life Technologies Corporation（现为赛默飞世尔科技公司的一部分）的企业发展高级副总裁，并于2007年5月至2008年11月担任Invitrogen Corporation的高级董事。1982年至2007年1月，Grossman博士在Applied Biosystems担任过各种领导职务，包括研究科学家、专利律师、知识产权副总裁和战略与业务发展副总裁。在Life Technologies Corporation及其前身公司（Invitrogen Corporation和Applied Biosystems）任职期间，Grossman博士领导了超过25项业务的收购或剥离，并负责超过4000项专利和许可的知识产权投资组合。Grossman博士目前代表Telegraph Hill Partners担任以下私人投资组合公司的董事:Agena Biosciences，Inc.，Argonaut Manufacturing Services，Inc.，Verogen，Inc.，Specific Diagnostics，Inc.和Nimble Therapeutics，Inc.。Grossman博士拥有加利福尼亚大学伯克利分校的化学工程学士学位和博士学位，弗吉尼亚大学的化学工程硕士学位和圣克拉拉大学法学院的法学博士学位。Grossman博士撰写了许多科学出版物，并拥有20多项美国专利。
Paul Grossman,has served as a director since January 2019 and has been a Partner of Telegraph Hill Partners since February 2014. Dr. Grossman previously served as Senior Vice President of Corporate Development for Life Technologies Corporation (now part of Thermo Fisher Scientific Inc.), from November 2008 to February 2014, and for Invitrogen Corporation from May 2007 to November 2008. From 1982 to January 2007, Dr. Grossman held a variety of leadership roles at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development. During his tenure at Life Technologies Corporation and its predecessor companies (Invitrogen Corporation and Applied Biosystems), Dr. Grossman led the acquisition or divestment of more than 25 businesses and was responsible for an intellectual property portfolio of over 4,000 patents and licenses. Dr. Grossman currently represents Telegraph Hill Partners as a director of the following private portfolio companies: Excellos, Argonaut Manufacturing Services, Inc., and Thomson Biosolutions, LLC. Dr. Grossman holds bachelor's and Ph.D. degrees in Chemical Engineering from the University of California, Berkeley, a master's degree in Chemical Engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law. Dr. Grossman has authored numerous scientific publications and holds more than 20 U.S. patents. - Paul Grossman自2019年1月起担任董事，并自2014年2月起担任风险投资公司Telegraph Hill Partners的合伙人，该公司积极参与生命科学，医疗器械和医疗保健行业中基于技术的成长型公司的发展。Grossman博士曾于2008年11月至2014年2月担任Life Technologies Corporation（现为赛默飞世尔科技公司的一部分）的企业发展高级副总裁，并于2007年5月至2008年11月担任Invitrogen Corporation的高级董事。1982年至2007年1月，Grossman博士在Applied Biosystems担任过各种领导职务，包括研究科学家、专利律师、知识产权副总裁和战略与业务发展副总裁。在Life Technologies Corporation及其前身公司（Invitrogen Corporation和Applied Biosystems）任职期间，Grossman博士领导了超过25项业务的收购或剥离，并负责超过4000项专利和许可的知识产权投资组合。Grossman博士目前代表Telegraph Hill Partners担任以下私人投资组合公司的董事:Agena Biosciences，Inc.，Argonaut Manufacturing Services，Inc.，Verogen，Inc.，Specific Diagnostics，Inc.和Nimble Therapeutics，Inc.。Grossman博士拥有加利福尼亚大学伯克利分校的化学工程学士学位和博士学位，弗吉尼亚大学的化学工程硕士学位和圣克拉拉大学法学院的法学博士学位。Grossman博士撰写了许多科学出版物，并拥有20多项美国专利。
- Paul Grossman,has served as a director since January 2019 and has been a Partner of Telegraph Hill Partners since February 2014. Dr. Grossman previously served as Senior Vice President of Corporate Development for Life Technologies Corporation (now part of Thermo Fisher Scientific Inc.), from November 2008 to February 2014, and for Invitrogen Corporation from May 2007 to November 2008. From 1982 to January 2007, Dr. Grossman held a variety of leadership roles at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development. During his tenure at Life Technologies Corporation and its predecessor companies (Invitrogen Corporation and Applied Biosystems), Dr. Grossman led the acquisition or divestment of more than 25 businesses and was responsible for an intellectual property portfolio of over 4,000 patents and licenses. Dr. Grossman currently represents Telegraph Hill Partners as a director of the following private portfolio companies: Excellos, Argonaut Manufacturing Services, Inc., and Thomson Biosolutions, LLC. Dr. Grossman holds bachelor's and Ph.D. degrees in Chemical Engineering from the University of California, Berkeley, a master's degree in Chemical Engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law. Dr. Grossman has authored numerous scientific publications and holds more than 20 U.S. patents.
- Alexander Herzick
-
Alexander Herzick自2019年1月起担任董事，并一直担任Telegraph Hill Partners的合伙人，Telegraph Hill Partners是一家风险投资公司，自2018年6月起积极参与生命科学，医疗器械和医疗保健行业中基于技术的成长型公司的发展。在2009年7月加入Telegraph Hill Partners之前，他于2005年6月至2007年6月担任BlueMountain Capital Management，LLC（现为Assured Investment Management，一家私有多元化资产管理公司）的投资组合经理，并担任美国银行（Bank of America，N.A.）的投资银行业务分析师，2003年6月至2005年6月在其证券部门工作。Herzick先生目前代表Telegraph Hill Partners担任以下私人投资组合公司的董事:Carterra，Inc.，Argonaut Manufacturing Services，Inc.和Dynex Technologies，Inc.。他还是Agena Bioscience的董事会观察员。Herzick先生拥有杜克大学经济学学士学位和西北大学凯洛格管理学院的MBA学位。
Alexander Herzick,has served as a director since January 2019 and has been a Partner of Telegraph Hill Partners since June 2018. Prior to joining Telegraph Hill Partners in July 2009, he served as a Portfolio Manager at BlueMountain Capital Management, LLC (now Assured Investment Management), a privately owned diversified asset manager, from June 2005 to June 2007, and as an Analyst in Investment Banking at Bank of America, N.A., in its Securities division, from June 2003 to June 2005. Mr. Herzick currently represents Telegraph Hill Partners as a director of the following private portfolio companies: Carterra, Inc., Argonaut Manufacturing Services, Inc., Cell Microsystems, Inc., Excellos, Inc., and Dynex Technologies, Inc. Mr. Herzick holds a bachelor's degree in Economics from Duke University and an MBA with honors from Northwestern University's Kellogg School of Management. - Alexander Herzick自2019年1月起担任董事，并一直担任Telegraph Hill Partners的合伙人，Telegraph Hill Partners是一家风险投资公司，自2018年6月起积极参与生命科学，医疗器械和医疗保健行业中基于技术的成长型公司的发展。在2009年7月加入Telegraph Hill Partners之前，他于2005年6月至2007年6月担任BlueMountain Capital Management，LLC（现为Assured Investment Management，一家私有多元化资产管理公司）的投资组合经理，并担任美国银行（Bank of America，N.A.）的投资银行业务分析师，2003年6月至2005年6月在其证券部门工作。Herzick先生目前代表Telegraph Hill Partners担任以下私人投资组合公司的董事:Carterra，Inc.，Argonaut Manufacturing Services，Inc.和Dynex Technologies，Inc.。他还是Agena Bioscience的董事会观察员。Herzick先生拥有杜克大学经济学学士学位和西北大学凯洛格管理学院的MBA学位。
- Alexander Herzick,has served as a director since January 2019 and has been a Partner of Telegraph Hill Partners since June 2018. Prior to joining Telegraph Hill Partners in July 2009, he served as a Portfolio Manager at BlueMountain Capital Management, LLC (now Assured Investment Management), a privately owned diversified asset manager, from June 2005 to June 2007, and as an Analyst in Investment Banking at Bank of America, N.A., in its Securities division, from June 2003 to June 2005. Mr. Herzick currently represents Telegraph Hill Partners as a director of the following private portfolio companies: Carterra, Inc., Argonaut Manufacturing Services, Inc., Cell Microsystems, Inc., Excellos, Inc., and Dynex Technologies, Inc. Mr. Herzick holds a bachelor's degree in Economics from Duke University and an MBA with honors from Northwestern University's Kellogg School of Management.
- Alexander Vos
-
Alexander Vos自2021年6月起担任董事，自2021年5月起担任新型基因疗法开发商Vectory Therapeutics BV的首席执行官，并担任Cimaas BV的监事会成员，自2018年9月以来，一家公司专注于开发针对特定肿瘤适应症的细胞免疫疗法。从2018年10月到2021年5月，他担任治疗性蛋白质制造商VARMX BV的首席执行官。从2018年9月至2021年5月，Vos先生担任Symeres BV（前身为Mercachem-Syncom）的董事会主席，Mercachem-Syncom是一家领先的欧洲合同研究组织，提供创新的化学解决方案。从2015年10月至2018年5月，沃斯先生担任再生医学联盟（再生和高级疗法的全球倡导者）的董事会成员。Vos先生于2009年11月至2017年12月担任Pharmacell B.V.（于2017年5月被Lonza AG收购）的首席执行官，这是一家专注于细胞和基因疗法的欧洲合同制造组织。在加入Pharmacell之前，Vos先生于2004年至2009年担任Paion AG（法兰克福证券交易所代码:PA8）的副首席执行官兼首席运营官，Paion AG是一家总部位于德国亚琛的制药公司，其创新药物可用于基于医院的镇静，麻醉和重症监护（中风）适应症。在加入Paion AG之前，Vos先生于2000年至2004年担任瑞士MediService AG（出售给Galenica AG）的首席执行官，该公司是欧洲领先的专业药房服务公司。从1994年到1999年，Vos先生在Genzyme Europe B.V.（总部位于荷兰的生物技术药物的制造商和开发商）担任过多个执行职务。在加入Genzyme之前，Vos先生于1989年至1994年在McKinsey&Company的制药业务部门工作。Vos先生拥有阿姆斯特丹大学药理学硕士学位和斯坦福大学商学院MBA学位。
Alexander Vos,has served as a director since June 2021, and also serves as Chairman of the Board of Scenic Biotech BV, a drug development company developing innovative medicines targeting neurodegenerative diseases leveraging its discovery platform that identifies gene modifiers, and as Chairman of the Board of Innocore Pharmaceuticals, which offers innovative polymer-based solutions for the sustained release of injectable biologics to the life science industry, and as Member of the Board at Roslin Cell Therapy a cell and gene therapy CDMO. Mr. Vos served as the Chief Executive Officer of VectorY Therapeutics BV, a developer of novel gene therapies, from May 2021 until November 2022. From October 2018 until May 2021, he served as Chief Executive Officer of VarmX BV, a manufacturer of therapeutic proteins. From September 2018 until May 2021, Mr. Vos served as Chairman of the board of directors of Symeres BV (formerly Mercachem-Syncom), a leading European contract research organization that offers innovative chemistry solutions. From October 2015 to May 2018, Mr. Vos served as a member of the board of directors of The Alliance for Regenerative Medicine, the global advocate for regenerative and advanced therapies. From November 2009 to December 2017, Mr. Vos served as Chief Executive Officer of PharmaCell B.V. (acquired by Lonza AG in May 2017) a European contract manufacturing organization focused exclusively on cell and gene therapy. Prior to PharmaCell, from 2004 to 2009, Mr. Vos served as Deputy-Chief Executive Officer and Chief Operating Officer of PAION AG (Frankfurt Stock Exchange: PA8), a pharmaceutical company with innovative drugs to be Alpha Teknova, Inc. ed in hospital-based sedation, anesthesia and critical care (stroke) indications headquartered in Aachen, Germany. Before PAION AG, from 2000 to 2004, Mr. Vos served as Chief Executive Officer of MediService AG in Switzerland (sold to Galenica AG), a leading specialty pharmacy service company in Europe. From 1994 to 1999, Mr. Vos held several executive roles in Genzyme Europe B.V., a manufacturer and developer of biotechnology drugs headquartered in the Netherlands. Prior to Genzyme, Mr. Vos worked from 1989 to 1994 for the pharmaceutical practice of McKinsey & Company. Mr. Vos holds a master's degree in Pharmacology from the University of Amsterdam and an MBA from Stanford University Graduate School of Business. - Alexander Vos自2021年6月起担任董事，自2021年5月起担任新型基因疗法开发商Vectory Therapeutics BV的首席执行官，并担任Cimaas BV的监事会成员，自2018年9月以来，一家公司专注于开发针对特定肿瘤适应症的细胞免疫疗法。从2018年10月到2021年5月，他担任治疗性蛋白质制造商VARMX BV的首席执行官。从2018年9月至2021年5月，Vos先生担任Symeres BV（前身为Mercachem-Syncom）的董事会主席，Mercachem-Syncom是一家领先的欧洲合同研究组织，提供创新的化学解决方案。从2015年10月至2018年5月，沃斯先生担任再生医学联盟（再生和高级疗法的全球倡导者）的董事会成员。Vos先生于2009年11月至2017年12月担任Pharmacell B.V.（于2017年5月被Lonza AG收购）的首席执行官，这是一家专注于细胞和基因疗法的欧洲合同制造组织。在加入Pharmacell之前，Vos先生于2004年至2009年担任Paion AG（法兰克福证券交易所代码:PA8）的副首席执行官兼首席运营官，Paion AG是一家总部位于德国亚琛的制药公司，其创新药物可用于基于医院的镇静，麻醉和重症监护（中风）适应症。在加入Paion AG之前，Vos先生于2000年至2004年担任瑞士MediService AG（出售给Galenica AG）的首席执行官，该公司是欧洲领先的专业药房服务公司。从1994年到1999年，Vos先生在Genzyme Europe B.V.（总部位于荷兰的生物技术药物的制造商和开发商）担任过多个执行职务。在加入Genzyme之前，Vos先生于1989年至1994年在McKinsey&Company的制药业务部门工作。Vos先生拥有阿姆斯特丹大学药理学硕士学位和斯坦福大学商学院MBA学位。
- Alexander Vos,has served as a director since June 2021, and also serves as Chairman of the Board of Scenic Biotech BV, a drug development company developing innovative medicines targeting neurodegenerative diseases leveraging its discovery platform that identifies gene modifiers, and as Chairman of the Board of Innocore Pharmaceuticals, which offers innovative polymer-based solutions for the sustained release of injectable biologics to the life science industry, and as Member of the Board at Roslin Cell Therapy a cell and gene therapy CDMO. Mr. Vos served as the Chief Executive Officer of VectorY Therapeutics BV, a developer of novel gene therapies, from May 2021 until November 2022. From October 2018 until May 2021, he served as Chief Executive Officer of VarmX BV, a manufacturer of therapeutic proteins. From September 2018 until May 2021, Mr. Vos served as Chairman of the board of directors of Symeres BV (formerly Mercachem-Syncom), a leading European contract research organization that offers innovative chemistry solutions. From October 2015 to May 2018, Mr. Vos served as a member of the board of directors of The Alliance for Regenerative Medicine, the global advocate for regenerative and advanced therapies. From November 2009 to December 2017, Mr. Vos served as Chief Executive Officer of PharmaCell B.V. (acquired by Lonza AG in May 2017) a European contract manufacturing organization focused exclusively on cell and gene therapy. Prior to PharmaCell, from 2004 to 2009, Mr. Vos served as Deputy-Chief Executive Officer and Chief Operating Officer of PAION AG (Frankfurt Stock Exchange: PA8), a pharmaceutical company with innovative drugs to be Alpha Teknova, Inc. ed in hospital-based sedation, anesthesia and critical care (stroke) indications headquartered in Aachen, Germany. Before PAION AG, from 2000 to 2004, Mr. Vos served as Chief Executive Officer of MediService AG in Switzerland (sold to Galenica AG), a leading specialty pharmacy service company in Europe. From 1994 to 1999, Mr. Vos held several executive roles in Genzyme Europe B.V., a manufacturer and developer of biotechnology drugs headquartered in the Netherlands. Prior to Genzyme, Mr. Vos worked from 1989 to 1994 for the pharmaceutical practice of McKinsey & Company. Mr. Vos holds a master's degree in Pharmacology from the University of Amsterdam and an MBA from Stanford University Graduate School of Business.
- Stephen Gunstream
-
Stephen Gunstream自2020年9月起担任董事，自2020年5月起担任我们的总裁兼首席执行官，并于2019年12月至2020年5月担任我们的首席商务官。Gunstream先生在生命科学行业拥有超过20年的销售、市场营销、研究与开发和一般管理经验。从2015年6月至2019年12月，Gunstream先生在全球医疗技术公司Becton Dickinson&Co.（纽约证券交易所代码:BDX）担任多个职务，最近担任BD Biosciences的副总裁兼总经理，负责领导BD&8217的流式细胞仪和基因组业务。从2008年到2015年，他曾担任Integrated DNA Technologies公司（定制核酸的领先供应商）的多种职务，最近担任首席商务官，在那里他负责产品开发、全球销售和全球营销。在Gunstream先生的领导下，IDT利用其核心DNA制造优势，推出了几种高度创新的产品，重新定位了公司在市场上的地位，包括Xgen Exome面板和Gblocks基因片段，他还因后者被任命为共同发明人。加入IDT之前，Gunstream从2001年到2008年在Applied Biosystems Inc.（现为赛默飞世尔科技公司的一部分）担任多个产品开发和业务开发职位，这是一家生物医学技术公司。Gunstream先生获得了西北大学生物医学工程学士学位和杜克大学福库商学院的MBA学位。他是10项已发布专利和超过25项未决专利的指定发明人。
Stephen Gunstream,has served as a director since September 2020 and as Alpha Teknova, Inc. President and Chief Executive Officer since May 2020, and served as Alpha Teknova, Inc. Chief Business Officer from December 2019 to May 2020. Mr. Gunstream has more than 20 years of sales, marketing, research and development, and general management experience in the life sciences industry. From June 2015 to December 2019, Mr. Gunstream served in multiple roles at Becton Dickinson & Co. ("BD") (NYSE: BDX), a global medical technology company, most recently as Vice President and General Manager of BD Biosciences, where he was responsible for leading BD's flow cytometry and genomics business. From 2008 to 2015, Mr. Gunstream served in multiple roles at Integrated DNA Technologies, Inc. ("IDT"), a leading supplier of custom nucleic acids, most recently as Chief Commercial Officer, where he was responsible for product development, global sales, and global marketing. Under Mr. Gunstream's leadership, IDT took advantage of its core DNA manufacturing strengths and launched several highly innovative products that repositioned the company in the market, including the xGen Exome Panel and gBlocks Gene Fragments, the latter for which he was also named a co-inventor. Prior to IDT, Mr. Gunstream held multiple product development and business development roles with Applied Biosystems Inc. (now part of Thermo Fisher Scientific Inc.), a biomedical technology company, from 2001 to 2008. Mr. Gunstream received a bachelor's degree in Biomedical Engineering from Northwestern University and an MBA from the Fuqua School of Business at Duke University. He is a named inventor on 11 issued patents and over 27 pending patents. - Stephen Gunstream自2020年9月起担任董事，自2020年5月起担任我们的总裁兼首席执行官，并于2019年12月至2020年5月担任我们的首席商务官。Gunstream先生在生命科学行业拥有超过20年的销售、市场营销、研究与开发和一般管理经验。从2015年6月至2019年12月，Gunstream先生在全球医疗技术公司Becton Dickinson&Co.（纽约证券交易所代码:BDX）担任多个职务，最近担任BD Biosciences的副总裁兼总经理，负责领导BD&8217的流式细胞仪和基因组业务。从2008年到2015年，他曾担任Integrated DNA Technologies公司（定制核酸的领先供应商）的多种职务，最近担任首席商务官，在那里他负责产品开发、全球销售和全球营销。在Gunstream先生的领导下，IDT利用其核心DNA制造优势，推出了几种高度创新的产品，重新定位了公司在市场上的地位，包括Xgen Exome面板和Gblocks基因片段，他还因后者被任命为共同发明人。加入IDT之前，Gunstream从2001年到2008年在Applied Biosystems Inc.（现为赛默飞世尔科技公司的一部分）担任多个产品开发和业务开发职位，这是一家生物医学技术公司。Gunstream先生获得了西北大学生物医学工程学士学位和杜克大学福库商学院的MBA学位。他是10项已发布专利和超过25项未决专利的指定发明人。
- Stephen Gunstream,has served as a director since September 2020 and as Alpha Teknova, Inc. President and Chief Executive Officer since May 2020, and served as Alpha Teknova, Inc. Chief Business Officer from December 2019 to May 2020. Mr. Gunstream has more than 20 years of sales, marketing, research and development, and general management experience in the life sciences industry. From June 2015 to December 2019, Mr. Gunstream served in multiple roles at Becton Dickinson & Co. ("BD") (NYSE: BDX), a global medical technology company, most recently as Vice President and General Manager of BD Biosciences, where he was responsible for leading BD's flow cytometry and genomics business. From 2008 to 2015, Mr. Gunstream served in multiple roles at Integrated DNA Technologies, Inc. ("IDT"), a leading supplier of custom nucleic acids, most recently as Chief Commercial Officer, where he was responsible for product development, global sales, and global marketing. Under Mr. Gunstream's leadership, IDT took advantage of its core DNA manufacturing strengths and launched several highly innovative products that repositioned the company in the market, including the xGen Exome Panel and gBlocks Gene Fragments, the latter for which he was also named a co-inventor. Prior to IDT, Mr. Gunstream held multiple product development and business development roles with Applied Biosystems Inc. (now part of Thermo Fisher Scientific Inc.), a biomedical technology company, from 2001 to 2008. Mr. Gunstream received a bachelor's degree in Biomedical Engineering from Northwestern University and an MBA from the Fuqua School of Business at Duke University. He is a named inventor on 11 issued patents and over 27 pending patents.
- Martha J. Demski
-
自2005年以来Martha J. Demski一直担任Equillium, Inc.的董事之一。自2011年8月以来她曾担任 Ajinimoto Althea, Inc. formerly Althea Technologies, Inc（全面集成的开发和生产组织）的高级副总裁兼首席财务官。从2008年7月到2010年12月她担任idney Kimmel Cancer Center （SKCC）（一个从事生物医学研究在2009年自愿申请破产非盈利的公司）的临时首席运营官和首席财务官。2006年4月至2008年5月担任U.S. Trust的高级副总裁。从2005年到2008年7月就职于Trustees at SKCC董事，审计委员会主席以及管理和提名委员会主席。从1988年12月到2004年6月担任Vical Incorporated（一家生物制药公司）副总裁、首席财务官、财务主管兼总监。她也担任Adamas Pharmaceuticals, Inc董事和审计委员会主席。她在密歇根州立大学获得了文学学士学位和芝加哥大学布斯商学院工商管理硕士学位。
Martha J. Demski,has served as a director since August 2023. Ms. Demski has extensive strategic, operational, biotech, and financial leadership experience. She has significant public company board experience, having served in various roles including Chair of the Board, Lead Independent Director, Audit Committee Chair, and Compensation Committee Member. She has served on the boards of Chimerix, Inc., Equillium, Inc., Adamas Pharmaceuticals, Inc., and ADMA Biologics, Inc. Ms. Demski also has extensive executive leadership experience, including serving as Chief Financial Officer and Chief Operating Officer at multiple companies. In addition, she spent 13 years with Bank of America, where she was an early leader in banking services for biotech companies in the San Diego region beginning in 1978. She has also served as a board member and advisor to various private companies and philanthropic organizations. Ms. Demski holds a B.A. from Michigan State University and an M.B.A. from the University of Chicago Booth School of Business, with concentrations in finance and accounting. In 2017, she received the Director of the Year in Corporate Governance award from the Corporate Directors Forum. - 自2005年以来Martha J. Demski一直担任Equillium, Inc.的董事之一。自2011年8月以来她曾担任 Ajinimoto Althea, Inc. formerly Althea Technologies, Inc（全面集成的开发和生产组织）的高级副总裁兼首席财务官。从2008年7月到2010年12月她担任idney Kimmel Cancer Center （SKCC）（一个从事生物医学研究在2009年自愿申请破产非盈利的公司）的临时首席运营官和首席财务官。2006年4月至2008年5月担任U.S. Trust的高级副总裁。从2005年到2008年7月就职于Trustees at SKCC董事，审计委员会主席以及管理和提名委员会主席。从1988年12月到2004年6月担任Vical Incorporated（一家生物制药公司）副总裁、首席财务官、财务主管兼总监。她也担任Adamas Pharmaceuticals, Inc董事和审计委员会主席。她在密歇根州立大学获得了文学学士学位和芝加哥大学布斯商学院工商管理硕士学位。
- Martha J. Demski,has served as a director since August 2023. Ms. Demski has extensive strategic, operational, biotech, and financial leadership experience. She has significant public company board experience, having served in various roles including Chair of the Board, Lead Independent Director, Audit Committee Chair, and Compensation Committee Member. She has served on the boards of Chimerix, Inc., Equillium, Inc., Adamas Pharmaceuticals, Inc., and ADMA Biologics, Inc. Ms. Demski also has extensive executive leadership experience, including serving as Chief Financial Officer and Chief Operating Officer at multiple companies. In addition, she spent 13 years with Bank of America, where she was an early leader in banking services for biotech companies in the San Diego region beginning in 1978. She has also served as a board member and advisor to various private companies and philanthropic organizations. Ms. Demski holds a B.A. from Michigan State University and an M.B.A. from the University of Chicago Booth School of Business, with concentrations in finance and accounting. In 2017, she received the Director of the Year in Corporate Governance award from the Corporate Directors Forum.
高管简历
中英对照 | 中文 | 英文- Stephen Gunstream
Stephen Gunstream自2020年9月起担任董事，自2020年5月起担任我们的总裁兼首席执行官，并于2019年12月至2020年5月担任我们的首席商务官。Gunstream先生在生命科学行业拥有超过20年的销售、市场营销、研究与开发和一般管理经验。从2015年6月至2019年12月，Gunstream先生在全球医疗技术公司Becton Dickinson&Co.（纽约证券交易所代码:BDX）担任多个职务，最近担任BD Biosciences的副总裁兼总经理，负责领导BD&8217的流式细胞仪和基因组业务。从2008年到2015年，他曾担任Integrated DNA Technologies公司（定制核酸的领先供应商）的多种职务，最近担任首席商务官，在那里他负责产品开发、全球销售和全球营销。在Gunstream先生的领导下，IDT利用其核心DNA制造优势，推出了几种高度创新的产品，重新定位了公司在市场上的地位，包括Xgen Exome面板和Gblocks基因片段，他还因后者被任命为共同发明人。加入IDT之前，Gunstream从2001年到2008年在Applied Biosystems Inc.（现为赛默飞世尔科技公司的一部分）担任多个产品开发和业务开发职位，这是一家生物医学技术公司。Gunstream先生获得了西北大学生物医学工程学士学位和杜克大学福库商学院的MBA学位。他是10项已发布专利和超过25项未决专利的指定发明人。
Stephen Gunstream,has served as a director since September 2020 and as Alpha Teknova, Inc. President and Chief Executive Officer since May 2020, and served as Alpha Teknova, Inc. Chief Business Officer from December 2019 to May 2020. Mr. Gunstream has more than 20 years of sales, marketing, research and development, and general management experience in the life sciences industry. From June 2015 to December 2019, Mr. Gunstream served in multiple roles at Becton Dickinson & Co. ("BD") (NYSE: BDX), a global medical technology company, most recently as Vice President and General Manager of BD Biosciences, where he was responsible for leading BD's flow cytometry and genomics business. From 2008 to 2015, Mr. Gunstream served in multiple roles at Integrated DNA Technologies, Inc. ("IDT"), a leading supplier of custom nucleic acids, most recently as Chief Commercial Officer, where he was responsible for product development, global sales, and global marketing. Under Mr. Gunstream's leadership, IDT took advantage of its core DNA manufacturing strengths and launched several highly innovative products that repositioned the company in the market, including the xGen Exome Panel and gBlocks Gene Fragments, the latter for which he was also named a co-inventor. Prior to IDT, Mr. Gunstream held multiple product development and business development roles with Applied Biosystems Inc. (now part of Thermo Fisher Scientific Inc.), a biomedical technology company, from 2001 to 2008. Mr. Gunstream received a bachelor's degree in Biomedical Engineering from Northwestern University and an MBA from the Fuqua School of Business at Duke University. He is a named inventor on 11 issued patents and over 27 pending patents.- Stephen Gunstream自2020年9月起担任董事，自2020年5月起担任我们的总裁兼首席执行官，并于2019年12月至2020年5月担任我们的首席商务官。Gunstream先生在生命科学行业拥有超过20年的销售、市场营销、研究与开发和一般管理经验。从2015年6月至2019年12月，Gunstream先生在全球医疗技术公司Becton Dickinson&Co.（纽约证券交易所代码:BDX）担任多个职务，最近担任BD Biosciences的副总裁兼总经理，负责领导BD&8217的流式细胞仪和基因组业务。从2008年到2015年，他曾担任Integrated DNA Technologies公司（定制核酸的领先供应商）的多种职务，最近担任首席商务官，在那里他负责产品开发、全球销售和全球营销。在Gunstream先生的领导下，IDT利用其核心DNA制造优势，推出了几种高度创新的产品，重新定位了公司在市场上的地位，包括Xgen Exome面板和Gblocks基因片段，他还因后者被任命为共同发明人。加入IDT之前，Gunstream从2001年到2008年在Applied Biosystems Inc.（现为赛默飞世尔科技公司的一部分）担任多个产品开发和业务开发职位，这是一家生物医学技术公司。Gunstream先生获得了西北大学生物医学工程学士学位和杜克大学福库商学院的MBA学位。他是10项已发布专利和超过25项未决专利的指定发明人。
- Stephen Gunstream,has served as a director since September 2020 and as Alpha Teknova, Inc. President and Chief Executive Officer since May 2020, and served as Alpha Teknova, Inc. Chief Business Officer from December 2019 to May 2020. Mr. Gunstream has more than 20 years of sales, marketing, research and development, and general management experience in the life sciences industry. From June 2015 to December 2019, Mr. Gunstream served in multiple roles at Becton Dickinson & Co. ("BD") (NYSE: BDX), a global medical technology company, most recently as Vice President and General Manager of BD Biosciences, where he was responsible for leading BD's flow cytometry and genomics business. From 2008 to 2015, Mr. Gunstream served in multiple roles at Integrated DNA Technologies, Inc. ("IDT"), a leading supplier of custom nucleic acids, most recently as Chief Commercial Officer, where he was responsible for product development, global sales, and global marketing. Under Mr. Gunstream's leadership, IDT took advantage of its core DNA manufacturing strengths and launched several highly innovative products that repositioned the company in the market, including the xGen Exome Panel and gBlocks Gene Fragments, the latter for which he was also named a co-inventor. Prior to IDT, Mr. Gunstream held multiple product development and business development roles with Applied Biosystems Inc. (now part of Thermo Fisher Scientific Inc.), a biomedical technology company, from 2001 to 2008. Mr. Gunstream received a bachelor's degree in Biomedical Engineering from Northwestern University and an MBA from the Fuqua School of Business at Duke University. He is a named inventor on 11 issued patents and over 27 pending patents.
- Matthew Lowell
Matthew Lowell自2021年2月起担任公司首席财务官。在加入Teknova之前，Lowell先生于2017年1月至2021年2月担任医疗设备公司Varex Imaging Corporation Nasdaq:VREX的财务副总裁兼司库，同时还领导业务开发活动。Lowell先生还于2013年4月至2016年12月担任瓦里安医疗系统公司（“；Varian”；）（纽约证券交易所代码:VAR）的财务副总裁，并于2017年1月从Varian剥离Varex Imaging Corporation，负责财务规划和分析以及业务发展。在加入Varian之前，Lowell先生从2002年到2013年在Abbott Medical Optics，Inc.及其前身Advanced Medical Optics，Inc.工作了10多年，担任各种战略，业务发展和财务职务。Lowell先生的投资银行职业生涯始于NationsBank，N.A.的投资银行部门，Donaldson，Lufkin&Jenrette，Inc.和瑞士信贷第一波士顿。他拥有北卡罗来纳大学教堂山分校的经济学学士学位和西北大学凯洛格管理学院的工商管理硕士学位。
Matthew Lowell,has served as Alpha Teknova, Inc. Chief Financial Officer since February 2021. Prior to joining Teknova, Mr. Lowell served as Vice President of Finance and Treasurer at Varex Imaging Corporation (NASDAQ: VREX), a medical device company, from January 2017 to February 2021 while also leading business development activity. Mr. Lowell also served as Vice President of Finance at Varian Medical Systems, Inc. ("Varian") (NYSE: VAR) from April 2013 to December 2016, prior to the spin-off of Varex Imaging Corporation from Varian in January 2017, with responsibility for financial planning and analysis as well as business development. Before joining Varian, Mr. Lowell spent over 10 years, from 2002 to 2013, at Abbott Medical Optics, Inc. and its predecessor, Advanced Medical Optics, Inc. in a variety of strategy, business development and finance roles. Mr. Lowell began his career in investment banking with positions at NationsBank, N.A. in its Investment Banking division, Donaldson, Lufkin & Jenrette, Inc. and Credit Suisse First Boston. He holds a bachelor's degree in Economics from the University of North Carolina at Chapel Hill and a master's degree in Business Administration from the Kellogg School of Management at Northwestern University.- Matthew Lowell自2021年2月起担任公司首席财务官。在加入Teknova之前，Lowell先生于2017年1月至2021年2月担任医疗设备公司Varex Imaging Corporation Nasdaq:VREX的财务副总裁兼司库，同时还领导业务开发活动。Lowell先生还于2013年4月至2016年12月担任瓦里安医疗系统公司（“；Varian”；）（纽约证券交易所代码:VAR）的财务副总裁，并于2017年1月从Varian剥离Varex Imaging Corporation，负责财务规划和分析以及业务发展。在加入Varian之前，Lowell先生从2002年到2013年在Abbott Medical Optics，Inc.及其前身Advanced Medical Optics，Inc.工作了10多年，担任各种战略，业务发展和财务职务。Lowell先生的投资银行职业生涯始于NationsBank，N.A.的投资银行部门，Donaldson，Lufkin&Jenrette，Inc.和瑞士信贷第一波士顿。他拥有北卡罗来纳大学教堂山分校的经济学学士学位和西北大学凯洛格管理学院的工商管理硕士学位。
- Matthew Lowell,has served as Alpha Teknova, Inc. Chief Financial Officer since February 2021. Prior to joining Teknova, Mr. Lowell served as Vice President of Finance and Treasurer at Varex Imaging Corporation (NASDAQ: VREX), a medical device company, from January 2017 to February 2021 while also leading business development activity. Mr. Lowell also served as Vice President of Finance at Varian Medical Systems, Inc. ("Varian") (NYSE: VAR) from April 2013 to December 2016, prior to the spin-off of Varex Imaging Corporation from Varian in January 2017, with responsibility for financial planning and analysis as well as business development. Before joining Varian, Mr. Lowell spent over 10 years, from 2002 to 2013, at Abbott Medical Optics, Inc. and its predecessor, Advanced Medical Optics, Inc. in a variety of strategy, business development and finance roles. Mr. Lowell began his career in investment banking with positions at NationsBank, N.A. in its Investment Banking division, Donaldson, Lufkin & Jenrette, Inc. and Credit Suisse First Boston. He holds a bachelor's degree in Economics from the University of North Carolina at Chapel Hill and a master's degree in Business Administration from the Kellogg School of Management at Northwestern University.
- Damon Terrill
Damon Terrill自2020年8月起担任我们的总法律顾问兼首席合规官。在加入Teknova之前，Terrill先生在罗克韦尔柯林斯公司（Collins Aerospace）（现为Collins Aerospace）和Raytheon Technologies Corp.（NYSE:RTX）的运营部门的总法律顾问办公室担任过多个领导职位。这些职务包括2019年2月至2020年8月的航空电子业务部门总法律顾问，2016年3月至2018年11月的内部系统业务部门OGC负责人以及2014年3月至2016年3月的商业系统业务部门负责人。加入Rockwell之前，Terrill从2006年1月到2013年12月担任IDT国际和资本市场高级副总裁and General Counsel。在加入IDT之前，Terrill先生于2002年至2005年在华盛顿特区的美国国务院担任律师顾问，并于1999年至2002年在华盛顿特区的高伟绅律师事务所（Clifford Chance LLP）担任合伙人。Terrill先生拥有爱荷华大学政治学学士学位，美国大学国际服务学院国际事务硕士学位和纽约大学法学院法学博士学位。Terrill先生获准在纽约州，哥伦比亚特区和爱荷华州从事法律工作。
Damon Terrill,has served as Alpha Teknova, Inc. General Counsel and Chief Compliance Officer since August 2020. Beginning in 2014 Mr. Terrill held a number of leadership positions within the Office of the General Counsel ("OGC") of Rockwell Collins, Inc. ("Collins"), now Collins Aerospace and an operating segment of Raytheon Technologies Corp. (NYSE: RTX). Those roles included General Counsel for the Avionics business segment and the OGC lead for both the Interior Systems and Commercial Systems businesses. Before joining Collins, Mr. Terrill served as Senior Vice President and General Counsel, International & Capital Markets, of Integrated DNA Technologies ("IDT") from 2006 to 2013. Prior to IDT, Mr. Terrill was an attorney-adviser at the U.S. Department of State in Washington, D.C., from 2002 to 2005, and an associate with Clifford Chance, LLP in Washington, D.C., from 1999 to 2002. Mr. Terrill holds a bachelor's degree in Political Science from the University of Iowa, a master's degree in International Affairs from the School of International Service, American University, and a J.D. from the New York University School of Law. Mr. Terrill is admitted to practice law in the State of New York, the District of Columbia, and the State of Iowa.- Damon Terrill自2020年8月起担任我们的总法律顾问兼首席合规官。在加入Teknova之前，Terrill先生在罗克韦尔柯林斯公司（Collins Aerospace）（现为Collins Aerospace）和Raytheon Technologies Corp.（NYSE:RTX）的运营部门的总法律顾问办公室担任过多个领导职位。这些职务包括2019年2月至2020年8月的航空电子业务部门总法律顾问，2016年3月至2018年11月的内部系统业务部门OGC负责人以及2014年3月至2016年3月的商业系统业务部门负责人。加入Rockwell之前，Terrill从2006年1月到2013年12月担任IDT国际和资本市场高级副总裁and General Counsel。在加入IDT之前，Terrill先生于2002年至2005年在华盛顿特区的美国国务院担任律师顾问，并于1999年至2002年在华盛顿特区的高伟绅律师事务所（Clifford Chance LLP）担任合伙人。Terrill先生拥有爱荷华大学政治学学士学位，美国大学国际服务学院国际事务硕士学位和纽约大学法学院法学博士学位。Terrill先生获准在纽约州，哥伦比亚特区和爱荷华州从事法律工作。
- Damon Terrill,has served as Alpha Teknova, Inc. General Counsel and Chief Compliance Officer since August 2020. Beginning in 2014 Mr. Terrill held a number of leadership positions within the Office of the General Counsel ("OGC") of Rockwell Collins, Inc. ("Collins"), now Collins Aerospace and an operating segment of Raytheon Technologies Corp. (NYSE: RTX). Those roles included General Counsel for the Avionics business segment and the OGC lead for both the Interior Systems and Commercial Systems businesses. Before joining Collins, Mr. Terrill served as Senior Vice President and General Counsel, International & Capital Markets, of Integrated DNA Technologies ("IDT") from 2006 to 2013. Prior to IDT, Mr. Terrill was an attorney-adviser at the U.S. Department of State in Washington, D.C., from 2002 to 2005, and an associate with Clifford Chance, LLP in Washington, D.C., from 1999 to 2002. Mr. Terrill holds a bachelor's degree in Political Science from the University of Iowa, a master's degree in International Affairs from the School of International Service, American University, and a J.D. from the New York University School of Law. Mr. Terrill is admitted to practice law in the State of New York, the District of Columbia, and the State of Iowa.